uniQure

News

uniQure sets course to US filing for Huntington gene therapy

Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.

News

New FDA knockback hits uniQure and Huntington patients hard

uniQure looks like it may have to run another trial of its Huntington's disease gene therapy AMT-130, delaying the highly anticipated programme.

News

uniQure poleaxed as FDA blocks Huntington's therapy

uniQure has revealed that the FDA has said it is not prepared to review its Huntington's gene therapy in what seems to be a change in policy.

News

Joy as uniQure Huntington's therapy clears pivotal trial

uniQure's gene therapy AMT-130 has cleared a trial in Huntington's, setting up filings and raising the prospect of a first treatment for the disease.

News

uniQure rockets on map to market for Huntington's therapy

uniQure says it has reached agreement with the FDA on a pathway to accelerated approval for its much-anticipated Huntington's disease gene therapy.

News

uniQure wields axe again as Huntington's therapy progresses

uniQure is shrinking again, saying it will shed two-thirds of its staff by the end of the year – about 300 jobs – as it tries to trim $75 million off its annual cash burn.

uniQure sets course to US filing for Huntington gene therapy

New FDA knockback hits uniQure and Huntington patients hard

uniQure poleaxed as FDA blocks Huntington's therapy

Joy as uniQure Huntington's therapy clears pivotal trial

uniQure rockets on map to market for Huntington's therapy

uniQure wields axe again as Huntington's therapy progresses

NICE says Libtayo can be used for advanced cervical cancer

Discover a new era of healthcare panel engagement: Grounded ...

uniQure

Editor's Picks